SG11201407220YA - N-alkyltriazole compounds as lpar antagonists - Google Patents
N-alkyltriazole compounds as lpar antagonistsInfo
- Publication number
- SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- compounds
- drive
- designated states
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062461 WO2013189864A1 (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407220YA true SG11201407220YA (en) | 2014-12-30 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407220YA SG11201407220YA (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9321738B2 (xx) |
| EP (1) | EP2864300A1 (xx) |
| JP (1) | JP2015520202A (xx) |
| KR (1) | KR20150021057A (xx) |
| CN (1) | CN104411692A (xx) |
| AU (1) | AU2013279512A1 (xx) |
| BR (1) | BR112014030685A2 (xx) |
| CA (1) | CA2869541A1 (xx) |
| CL (1) | CL2014003243A1 (xx) |
| CO (1) | CO7131358A2 (xx) |
| CR (1) | CR20140525A (xx) |
| EA (1) | EA201492285A1 (xx) |
| HK (1) | HK1206342A1 (xx) |
| IL (1) | IL236088A0 (xx) |
| IN (1) | IN2014DN09348A (xx) |
| MA (1) | MA37764A1 (xx) |
| MX (1) | MX2014014710A (xx) |
| PE (1) | PE20142448A1 (xx) |
| PH (1) | PH12014502789A1 (xx) |
| SG (1) | SG11201407220YA (xx) |
| UA (1) | UA109868C2 (xx) |
| WO (1) | WO2013189864A1 (xx) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| CA2869564A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-aryltriazole compounds as lpar antagonists |
| US10000459B2 (en) | 2013-03-15 | 2018-06-19 | Epigen Biosciences, Inc. | Heterocyclic compounds useful in the treatment of disease |
| CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| AR108838A1 (es) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
| ES2943661T3 (es) | 2017-12-19 | 2023-06-15 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA |
| US11312706B2 (en) | 2017-12-19 | 2022-04-26 | Bristol-Myers Squibb Company | Cyclohexyl acid pyrazole azines as LPA antagonists |
| WO2019126087A1 (en) * | 2017-12-19 | 2019-06-27 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azoles as lpa antagonists |
| MX2020005874A (es) | 2017-12-19 | 2020-08-13 | Bristol Myers Squibb Co | Acidos carbamoil ciclohexilicos n-enlazados a pirazol como antagonistas de receptores del acido lisofosfatidico (lpa). |
| EP3728209A1 (en) | 2017-12-19 | 2020-10-28 | Bristol-Myers Squibb Company | Cyclohexyl acid isoxazole azines as lpa antagonists |
| US11180488B2 (en) | 2017-12-19 | 2021-11-23 | Bristol-Myers Squibb Company | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists |
| CN112041029A (zh) | 2017-12-19 | 2020-12-04 | 百时美施贵宝公司 | 作为lpa拮抗剂的环己基酸吡唑唑类 |
| PE20210655A1 (es) * | 2017-12-19 | 2021-03-31 | Bristol Myers Squibb Co | Carbamoil ciclohexil acidos ligados a n de triazol como antagonistas de lpa |
| JP7280881B2 (ja) * | 2017-12-19 | 2023-05-24 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール |
| US11447475B2 (en) | 2017-12-19 | 2022-09-20 | Bristol-Myers Squibb Company | Isoxazole N-linked carbamoyl cyclohexyl acids as LPA antagonists |
| BR112020011965A2 (pt) * | 2017-12-19 | 2020-11-17 | Bristol-Myers Squibb Company | triazol azinas de ácido ciclo-hexílico como antagonistas de lpa |
| KR20200112860A (ko) * | 2017-12-29 | 2020-10-05 | 바이오마린 파머수티컬 인크. | 질환의 치료를 위한 글리콜레이트 산화효소 억제제 |
| WO2020060916A1 (en) * | 2018-09-18 | 2020-03-26 | Bristol-Myers Squibb Company | Cycloheptyl acids as lpa antagonists |
| JP7427658B2 (ja) * | 2018-09-18 | 2024-02-05 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
| JP7412424B2 (ja) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| KR20220101137A (ko) * | 2019-11-15 | 2022-07-19 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도 |
| CA3185689A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| AU2022405082A1 (en) | 2021-12-08 | 2024-07-11 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) * | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| PE20140879A1 (es) * | 2010-12-07 | 2014-08-06 | Amira Pharmaceuticals Inc | Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| AU2012296662A1 (en) * | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
-
2013
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/zh active Pending
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/ko not_active Application Discontinuation
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
- 2013-06-17 EA EA201492285A patent/EA201492285A1/ru unknown
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/pt not_active Application Discontinuation
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/es not_active Application Discontinuation
- 2013-06-17 UA UAA201500428A patent/UA109868C2/ru unknown
- 2013-06-17 MA MA37764A patent/MA37764A1/fr unknown
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/ja not_active Ceased
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en active Application Filing
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/es unknown
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/es unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/es unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/es unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
-
2015
- 2015-07-21 HK HK15106927.8A patent/HK1206342A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9321738B2 (en) | 2016-04-26 |
| KR20150021057A (ko) | 2015-02-27 |
| WO2013189864A1 (en) | 2013-12-27 |
| BR112014030685A2 (pt) | 2017-06-27 |
| PE20142448A1 (es) | 2015-01-28 |
| IN2014DN09348A (xx) | 2015-07-17 |
| PH12014502789A1 (en) | 2015-02-09 |
| IL236088A0 (en) | 2015-02-01 |
| CO7131358A2 (es) | 2014-12-01 |
| UA109868C2 (xx) | 2015-10-12 |
| MX2014014710A (es) | 2015-03-04 |
| MA37764A1 (fr) | 2016-01-29 |
| JP2015520202A (ja) | 2015-07-16 |
| HK1206342A1 (en) | 2016-01-08 |
| US20150133511A1 (en) | 2015-05-14 |
| EA201492285A1 (ru) | 2015-04-30 |
| CN104411692A (zh) | 2015-03-11 |
| CR20140525A (es) | 2015-01-12 |
| AU2013279512A1 (en) | 2014-10-16 |
| CL2014003243A1 (es) | 2015-03-20 |
| CA2869541A1 (en) | 2013-12-27 |
| EP2864300A1 (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases |